Results 91 to 100 of about 170,404 (235)
The THESEUS Space Mission and the Infrared Telescope Calibration Unit
Astronomische Nachrichten, EarlyView.ABSTRACT The Transient High‐Energy Sky and Early Universe Surveyor (THESEUS) is an ESA M7 mission concept currently in Phase A, designed to exploit gamma‐ray bursts to probe the early Universe while advancing multi‐messenger and time‐domain astrophysics. To achieve its ambitious goals, THESEUS will combine wide‐band x‐ray and gamma‐ray monitors with an
András Péter Joó +9 more
wiley +1 more source
International Variation in Preoperative SNOT‐22 Scores: A Scoping Review and Exploratory Analysis
International Forum of Allergy &Rhinology, EarlyView.
Jaynelle Gao +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić +8 more
wiley +1 more source
British Educational Research Journal, EarlyView.Abstract Research evidence is mixed on the consequences of ability grouping policies, but most research has found an overrepresentation of disadvantaged social demographics in low‐ability groups. However, researchers have neglected to explain why ability grouping policies vary between countries.
Monica Reichenberg +2 more
wiley +1 more source